Search clinical trials for: Severe viral Pneumonia

Total 33851 results

Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen

Completed

A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19 (CAPSID)

COVID-19

Germany
University Hospital, Ghent
UCB Pharma

Completed

Zilucoplan® in Improving Oxygenation, Short-, Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failure (ZILU-COV)

COVID-19

Belgium
Immune Biosolutions Inc

Completed

Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness

COVID-19

Ukraine, South Africa
GeneOne Life Science, Inc.

Active, not recruiting

GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)

SARS-CoV Infection | Pneumonitis

Korea, Republic of, Puerto Rico, United States, Bulgaria, North Macedonia
Apogenix GmbH

Terminated

Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease (ASUCOV)

COVID-19

Spain, Germany, France, Italy, South Africa, India, Austria, Georgia, Poland
Rigel Pharmaceuticals

Completed

Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

Pneumonia, Viral | Pneumonia | Covid19 | SARS (Severe Acute Respiratory Syndrome) | SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere | SARS Pneumonia

United States, Argentina, Brazil, Mexico
aTyr Pharma, Inc.

Completed

Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

SARS-CoV-2 (COVID-19) Severe Pneumonia

United States, Puerto Rico
University Hospital, Montpellier

Completed

Longitudinal Follow-up of Patients With Chronic Inflammatory Rheumatisms (CIRs) Vaccinated Against COVID-19 Compared to Patients Refusing Vaccination (COVID-RIC3)

COVID-19 | Rheumatic Diseases | SARS-CoV Infection

France
Emory University
National Cancer Institute (NCI)

Active, not recruiting

Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19 (RESCUE1-19)

Severe Acute Respiratory Syndrome | Pneumonia | Symptomatic COVID-19 Infection Laboratory-Confirmed

United States
Airway Therapeutics, Inc.

Terminated

A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia

COVID-19 | Undefined

United States
Tasly Pharmaceuticals, Inc.
Tasly Pharmaceutical Group Co., Ltd

No longer available

Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19

Covid19

United States
Ophirex, Inc.
Premier Research Group plc

Terminated

Study of Varespladib in Patients Hospitalized With Severe COVID-19 (STAIRS)

Coronavirus Disease 2019 | Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2

United States
Mayo Clinic

Completed

CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2))

Diabetes Mellitus | Covid19

United States
National Taiwan University Hospital
Min-Sheng General Hospital; National Yang Ming Chiao Tung University Hospital

Completed

Using Mixed-methods Approach to Explore the Long-term Effects of COVID-19

Covid19

Taiwan
Oneness Biotech Co., Ltd.

Completed

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants

Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)

United States
Jena University Hospital
German Federal Ministry of Education and Research; Celltrion

Completed

Infliximab in the Treatment of Patients With Severe COVID-19 Disease (INFLIXCOVID)

COVID-19

Germany
Institut Pasteur

Completed

Longitudinal Follow-up of a Population Cohort in a French City With High SARS-CoV-2 Circulation, in Early 2020 [COVID-19] (COVID-OISE)

Covid19 | SARS (Severe Acute Respiratory Syndrome)

France
Institut Pasteur

Completed

Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France (CORSER)

COVID-19 | SARS (Severe Acute Respiratory Syndrome)

France
Peking Union Medical College Hospital

Completed

Single-cell Landscape of BALF in Patients With Severe ARDS and CARDS

Covid19 | ARDS: Acute Respiratory Distress Syndrome

China
Hospital Departamental de Villavicencio
Cooperative University of Colombia; Clinica Primavera; Clínica Meta; Grupo de Investigación...

Withdrawn

Characteristics of Patients With COVID-19 in Meta State, Colombia

SARS-CoV 2 | COVID | SARS (Severe Acute Respiratory Syndrome) | SARS (Disease) | SARS Pneumonia
MetrioPharm AG
Syneos Health, LLC

Completed

MP1032 Treatment in Patients With Moderate to Severe COVID-19

COVID-19

Spain, United States, Italy, France, Bulgaria, Hungary, Romania
National Institute of Allergy and Infectious Diseases...
PPD; University of Washington; Vanderbilt University Medical Center; Implicit Bioscience

Terminated

COVID-19 and Anti-CD14 Treatment Trial (CaTT)

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Coronavirus Disease 2019 (COVID-19)

United States
Arrowhead Regional Medical Center

Completed

Insulin Regulation and Severity of Severe Acute Respiratory Syndrome COVID-19 Infection

COVID-19 | Diabetes Mellitus | COVID-19 Pneumonia | COVID-19 Respiratory Infection

United States
EyePoint Pharmaceuticals, Inc.
Medical Technology Enterprise Consortium (MTEC)

Terminated

Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019 (RESCUE)

COVID-19 | Acute Respiratory Distress Syndrome (ARDS)

United States
Oxford University Clinical Research Unit, Vietnam
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam

Completed

Awake Prone Positioning in Moderate to Severe COVID-19

COVID-19 | SARS-CoV2 Infection | Respiratory Distress Syndrome, Adult | Acute Hypoxemic Respiratory Failure | COVID-19 Acute Respiratory Distress Syndrome

Vietnam
Takeda

Completed

A Study of TAK-019 in Healthy Japanese Adults (COVID-19)

Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Japan
InflaRx GmbH

Completed

Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia (PANAMO)

Severe COVID-19 Pneumonia

Belgium, Brazil, France, Germany, Mexico, Netherlands, Peru, Russian Federation, South Africa
Memorial Sloan Kettering Cancer Center

Terminated

Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection

COVID-19

United States
Milton S. Hershey Medical Center

Withdrawn

Inhaled GM-CSF for Respiratory Virus-Associated Severe Pneumonia (iGRASP)

Pneumonia | Acute Respiratory Distress Syndrome | Respiratory Virus Infection
University of Saskatchewan
Government of Canada; Government of Saskatchewan

Active, not recruiting

A Clinical Trial to Study the COVAC-1 Booster Dose in Generally Healthy Adults

Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Canada
University of Manitoba
Research Manitoba

Completed

The CHILD Cohort COVID-19 Add-On Study

Covid19 | SARS-CoV Infection

Canada
Soroka University Medical Center
Roche Pharma AG

Completed

Treatment With Pirfenidone for COVID-19 Related Severe ARDS

Covid19 | ARDS

Israel
University of Texas Southwestern Medical Center

Terminated

Cardiovascular Implications of COVID-19

COVID-19 | SARS-CoV 2 | SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere | Cardiac Complication | SARS Pneumonia

United States
AnteoTech Ltd

Terminated

EuGeni Rapid Antigen Test for the Qualitative Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Causing COVID19 Disease in Compliance With the World Health Organization (WHO) (WHO)

SARS-CoV-2 Infection

Croatia, Greece, Spain
Northwestern University

Suspended

Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19

Covid19

United States
Gilead Sciences

Terminated

Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19) (REDPINE)

COVID-19

Spain, United States, United Kingdom, Portugal, Brazil, South Africa
University of Pavia
Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria

Completed

Muscle Weakness in COVID-19 Patients (MIOCOVID)

Covid19 | Muscle Weakness | SARS-CoV Infection | Exercise Intolerance

Italy
Direction Centrale du Service de Santé des Armées

Completed

Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020 (Covaé)

Covid19 | SARS-CoV Infection

France
University Hospital, Tours
Institut National de la Santé Et de la Recherche Médicale, France

Completed

Health cAre woRkers exposeD to COVID-19 (HARD-COVID19)

Depression | Burnout, Professional | Post Traumatic Stress Disorder

France
University of Giessen

Completed

GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia (GI-COVID)

COVID-19 Pneumonia | Severe Acute Respiratory Syndrome (SARS) Pneumonia

Germany
U.S. Army Medical Research and Development Command

No longer available

Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)

Severe Acute Respiratory Syndrome Coronavirus 2

United States, Germany, Afghanistan, Djibouti, Guam, Iraq, Japan, Kuwait
Pfizer

Completed

A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection

COVID-19

United States, Russian Federation, Thailand, Czechia, Colombia, Bulgaria, Japan, South Africa, Turkey, Argentina, Hungary, Malaysia, Mexico, Poland, Spain, Ukraine, Brazil
I-Mab Biopharma Co. Ltd.

Completed

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

Coronavirus Disease 2019 COVID-19

United States
National Institute of Allergy and Infectious Diseases...
National Heart, Lung, and Blood Institute (NHLBI); Gilead Sciences; University... and other collaborators

Completed

ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 (TESICO)

Covid19

United States
Groupe Hospitalier Paris Saint Joseph

Completed

Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group Infected With Severe Acute Respiratory Syndrome Coronavirus 2. (PERSO-COVID)

COVID-19

France
Groupe Hospitalier Pitie-Salpetriere
CMC Ambroise Paré; Centre Hospitalier Intercommunal Robert Ballanger; Centre...

Completed

Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study

Pneumonia | Covid-19 | ARDS

France
Elizabeth Glaser Pediatric AIDS Foundation
Find; Kiambu County

Completed

Antigen Rapid Diagnostic Tests for Community Identification of Severe Acute Respiratory Syndrome Coronavirus 2

Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Kenya
CMN "20 de Noviembre"

Active, not recruiting

Estrogen Therapy in Non-severe COVID-19 Patients

Covid-19

Mexico
Hospices Civils de Lyon

Completed

Host-pathogen Interactions During SARS-CoV-2 Infection (HPI-COVID-19)

Severe Acute Respiratory Syndrome Coronavirus 2 | Infection, Coronavirus

France
Certara
Bill and Melinda Gates Foundation; Parexel

Completed

International Registry of Healthcare Workers Exposed to COVID-19 Patients (UNITY Global) (UNITY Global)

Covid19 | SARS-CoV Infection

Pakistan

Search clinical trials for: Severe viral Pneumonia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations